Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Return on Equity (2016 - 2025)

ImmunityBio (IBRX) has disclosed Return on Equity for 11 consecutive years, with 0.69% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Equity rose 2.0% to 0.69% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.69%, a 2.0% increase, with the full-year FY2025 number at 0.71%, down 6.0% from a year prior.
  • Return on Equity was 0.69% for Q4 2025 at ImmunityBio, up from 0.64% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 1.88% in Q3 2021 to a low of 0.63% in Q2 2025.
  • A 5-year average of 1.04% and a median of 0.91% in 2023 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: plummeted -7196bps in 2021, then increased 22bps in 2023.
  • ImmunityBio's Return on Equity stood at 1.61% in 2021, then plummeted by -41bps to 0.95% in 2022, then grew by 23bps to 1.17% in 2023, then tumbled by -43bps to 0.67% in 2024, then increased by 2bps to 0.69% in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Return on Equity are 0.69% (Q4 2025), 0.64% (Q3 2025), and 0.63% (Q2 2025).